Draft:TissueLabs
Tissue Engineering Company
From Wikipedia, the free encyclopedia
TissueLabs is a Swiss biotechnology company focused on tissue engineering and organ biofabrication.[1]
Submission declined on 13 April 2026 by Superboilles (talk).
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
Submission declined on 19 February 2026 by ChrysGalley (talk). This draft reads like an advertisement. Wikipedia is an encyclopedia, not a platform for promotion or marketing. Drafts that are exclusively promotional may be deleted without notice.
Declined by ChrysGalley 59 days ago.Wikipedia articles must be written neutrally in a formal, impersonal, and dispassionate way. They should not read like a blog post, advertisement, or fan page. Rewrite the draft to remove:
Instead, only summarize in your own words a range of independent, reliable, published sources that discuss the subject. If you have a conflict of interest (e.g. you are the subject, an employee, or a relative) or are being paid to edit, you must disclose this to comply with Wikipedia's Terms of Use. | |
This draft reads like an advertisement. Wikipedia is an encyclopedia, not a platform for promotion or marketing. Drafts that are exclusively promotional may be deleted without notice.
Declined by Bonadea 2 months ago.Wikipedia articles must be written neutrally in a formal, impersonal, and dispassionate way. They should not read like a blog post, advertisement, or fan page. Rewrite the draft to remove:
Instead, only summarize in your own words a range of independent, reliable, published sources that discuss the subject. If you have a conflict of interest (e.g. you are the subject, an employee, or a relative) or are being paid to edit, you must disclose this to comply with Wikipedia's Terms of Use. | |
Comment: It is still very much in promotional language rather than that of an encyclopedia. For example "used by research laboratories worldwide" is not what an encyclopedia will say. The aspiration of an artificial cardiac device is what a company promotion would say, not an encyclopedia.If you have a conflict of interest under WP:COI then for important transparency reasons this needs to be declared fully. ChrysGalley (talk) 10:38, 19 February 2026 (UTC)
| Company type | Private |
|---|---|
| Industry | Bioengineering |
| Founded | 02/01/2019 |
| Founder | |
Key people | |
| Products | 3D Bioprinters and Biomaterials |
Number of employees | ~10 |
| Website | https://www.tissuelabs.com/ |
Founded in 2019 by Gabriel Liguori and Emerson Moretto, the company develops a biofabrication platform that includes 3D bioprinters and tissue-specific biomaterials intended to mimic aspects of human tissue environments. [1]According to the company, its platform is used in research settings for applications such as drug testing, disease modeling, and experimental tissue fabrication.[1]
According to statements by the company and its founder, Gabriel Liguori, TissueLabs is pursuing research into the development of a bioartificial heart using patient-derived cells. In a 2021 interview, Liguori stated that clinical trials for such a device could require an additional 10–15 years of research and development.[1]
TissueLabs is headquartered in Bellinzona, Ticino, Switzerland.[1]
History
Founding
TissueLabs was founded in 2019 in Brazil by Gabriel Liguori and Emerson Moretto. Liguori was included in the Forbes Under 30 list in 2018 [1] and named to the MIT Technology Review Innovators Under 35 list in 2020.[2] According to published accounts, his background includes work in cardiovascular regenerative medicine and tissue engineering.[1] The company originated from the Cietec incubator at the University of São Paulo and received seed funding to develop its biofabrication platform.[1]
Founded in 2019 by Gabriel Liguori and Emerson Moretto, the company relocated from Brazil to Switzerland, where it is headquartered in Bellinzona, Ticino.[1]
Early Years
During its early development, TissueLabs focused on tools for laboratory research in tissue engineering and biofabrication. In 2019, the company introduced MatriXpec, a series of tissue-specific hydrogels intended to model aspects of the extracellular matrix. By 2020, formulations had been developed for multiple tissue types, including myocardium, lung, liver, kidney, and cartilage, for use in three-dimensional cell culture and bioprinting applications.[3][4]
In early 2020, during the COVID-19 pandemic, TissueLabs reported that it redirected part of its research toward MatriWell, an in vitro system for studying SARS-CoV-2 infection in lung tissue.[5] The system combined a cell culture insert with lung-derived hydrogels to model aspects of three-dimensional lung epithelium and was made available for research use in studies of viral effects on pulmonary cells.[1]
In parallel with its biomaterials work, the company developed hardware for tissue engineering research. In 2020, it introduced TissueStart, an extrusion-based 3D bioprinter intended for academic and laboratory use.
Growth
In 2021, TissueLabs introduced TissueRay, an MSLA-based 3D bioprinter, which was presented at a meeting of the Tissue Engineering and Regenerative Medicine International Society (TERMIS).[6]
By late 2023, the company had raised funding to support its operations in Switzerland, including the establishment of a facility in Bellinzona that began operating in early 2024.
In 2024, TissueLabs was selected to participate in the Venture Leaders Biotech program, a Swiss initiative supporting biotechnology startups. In 2025, the company was included in the Top 100 Startups to Watch list published by Pequenas Empresas & Grandes Negócios (PEGN).[7] In the same year, TissueLabs introduced TissuePro, a 3D bioprinter intended for more complex tissue engineering applications.[8]
- provide significant coverage: discuss the subject in detail, not just brief mentions or routine announcements;
- are reliable: from reputable outlets with editorial oversight;
- are independent: not connected to the subject, such as interviews, press releases, the subject's own website, or sponsored content.
Please add references that meet all three of these criteria. If none exist, the subject is not yet suitable for Wikipedia.